Clonal Cytopenia of Undetermined Significance

2
Pipeline Programs
2
Companies
2
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Bristol Myers Squibb
1 program
1
EnasidenibPhase 2Small Molecule1 trial
Active Trials
NCT06240754Recruiting15Est. Feb 2029
Astex Pharmaceuticals
Astex PharmaceuticalsUK - Cambridge
1 program
1
InqoviPhase 11 trial
Active Trials
NCT06802146RecruitingEst. Dec 2028

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
2029
Bristol Myers SquibbEnasidenib
Astex PharmaceuticalsInqovi

Clinical Trials (2)

Total enrollment: 15 patients across 2 trials

NCT06240754Bristol Myers SquibbEnasidenib

Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial

Start: Oct 2024Est. completion: Feb 202915 patients
Phase 2Recruiting
NCT06802146Astex PharmaceuticalsInqovi

Early Intervention in High Risk CCUS

Start: Feb 2025Est. completion: Dec 2028
Phase 1Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 15 patients
2 companies competing in this space